DE3240174C2 - - Google Patents
Info
- Publication number
- DE3240174C2 DE3240174C2 DE3240174A DE3240174A DE3240174C2 DE 3240174 C2 DE3240174 C2 DE 3240174C2 DE 3240174 A DE3240174 A DE 3240174A DE 3240174 A DE3240174 A DE 3240174A DE 3240174 C2 DE3240174 C2 DE 3240174C2
- Authority
- DE
- Germany
- Prior art keywords
- urokinase
- molecular weight
- triazine
- polyethylene glycol
- glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 151
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 151
- 229960005356 urokinase Drugs 0.000 claims description 140
- 229920001223 polyethylene glycol Polymers 0.000 claims description 57
- 239000002202 Polyethylene glycol Substances 0.000 claims description 54
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 35
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 27
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 229940127126 plasminogen activator Drugs 0.000 claims description 27
- 229920001451 polypropylene glycol Polymers 0.000 claims description 25
- 239000007822 coupling agent Substances 0.000 claims description 15
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 230000003053 immunization Effects 0.000 claims description 11
- FKCZBCAVNSXTFW-UHFFFAOYSA-N 6-chloro-1h-1,3,5-triazin-2-one Chemical compound ClC1=NC=NC(=O)N1 FKCZBCAVNSXTFW-UHFFFAOYSA-N 0.000 claims description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001766 physiological effect Effects 0.000 claims description 3
- 229960000103 thrombolytic agent Drugs 0.000 claims description 3
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 55
- -1 acyl azide Chemical class 0.000 description 49
- 230000000694 effects Effects 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 30
- 238000001816 cooling Methods 0.000 description 25
- 238000000502 dialysis Methods 0.000 description 24
- 239000008363 phosphate buffer Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 102000013566 Plasminogen Human genes 0.000 description 16
- 108010051456 Plasminogen Proteins 0.000 description 16
- 150000003918 triazines Chemical class 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 102000009123 Fibrin Human genes 0.000 description 13
- 108010073385 Fibrin Proteins 0.000 description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 229950003499 fibrin Drugs 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000002504 physiological saline solution Substances 0.000 description 13
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 11
- 229920000573 polyethylene Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000004743 Polypropylene Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000002806 plasmin inhibitor Substances 0.000 description 9
- 229920001155 polypropylene Polymers 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108700023418 Amidases Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 108010088842 Fibrinolysin Proteins 0.000 description 8
- 229940122791 Plasmin inhibitor Drugs 0.000 description 8
- 102000005922 amidase Human genes 0.000 description 8
- 229940012957 plasmin Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- OMRXVBREYFZQHU-UHFFFAOYSA-N 2,4-dichloro-1,3,5-triazine Chemical compound ClC1=NC=NC(Cl)=N1 OMRXVBREYFZQHU-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920001281 polyalkylene Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 235000019256 formaldehyde Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- WFJRIDQGVSJLLH-UHFFFAOYSA-N methyl n-aminocarbamate Chemical compound COC(=O)NN WFJRIDQGVSJLLH-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- OPOJRMTZHYUKLY-UHFFFAOYSA-N 1h-1,3,5-triazin-2-one Chemical compound O=C1N=CN=CN1 OPOJRMTZHYUKLY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- OWADBEARODPFNF-UHFFFAOYSA-N C1=CC(=CC=C1C(C(CO)O)OC(C2=CC=C(C=C2)[N+](=O)[O-])C(CO)O)[N+](=O)[O-] Chemical compound C1=CC(=CC=C1C(C(CO)O)OC(C2=CC=C(C=C2)[N+](=O)[O-])C(CO)O)[N+](=O)[O-] OWADBEARODPFNF-UHFFFAOYSA-N 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QOHNHTHTTUJQEY-UHFFFAOYSA-N methyl n-diazocarbamate Chemical compound COC(=O)N=[N+]=[N-] QOHNHTHTTUJQEY-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56172908A JPS5896026A (ja) | 1981-10-30 | 1981-10-30 | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| CA000443230A CA1217718A (en) | 1981-10-30 | 1983-12-14 | Plasminogen activator derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3240174A1 DE3240174A1 (de) | 1983-05-19 |
| DE3240174C2 true DE3240174C2 (enExample) | 1990-08-23 |
Family
ID=25670236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823240174 Granted DE3240174A1 (de) | 1981-10-30 | 1982-10-29 | Neue plasminogen-aktivatorderivate |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4495285A (enExample) |
| JP (1) | JPS5896026A (enExample) |
| BR (1) | BR8206347A (enExample) |
| CA (1) | CA1203764A (enExample) |
| CH (1) | CH658669A5 (enExample) |
| DE (1) | DE3240174A1 (enExample) |
| FR (1) | FR2515684B1 (enExample) |
| GB (1) | GB2110219B (enExample) |
| SE (1) | SE457800B (enExample) |
Families Citing this family (197)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| JPS59196824A (ja) * | 1983-04-21 | 1984-11-08 | Kowa Co | 吸着防止剤 |
| JPS60176586A (ja) * | 1984-02-21 | 1985-09-10 | Sanwa Kagaku Kenkyusho:Kk | 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤 |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| JPS61176532A (ja) * | 1985-01-30 | 1986-08-08 | Green Cross Corp:The | プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法 |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4844897A (en) * | 1985-09-13 | 1989-07-04 | Hiroshi Maeda | Anti-tumor protease preparations |
| JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| NZ225880A (en) * | 1987-08-21 | 1991-07-26 | Wellcome Found | A complex of polyethylene glycol and tissue plasminogen activator |
| US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
| US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| IT1260468B (it) * | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US20030171292A1 (en) * | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| JPH08502082A (ja) * | 1992-07-02 | 1996-03-05 | コラーゲン コーポレイション | 生体適合性ポリマー結合体 |
| EP0672144A1 (en) * | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6 receptor antagonists |
| EP0749494A1 (en) | 1994-03-07 | 1996-12-27 | Chiron Corporation | Compositions for the inhibition of tnf formation and uses thereof |
| US7883693B2 (en) * | 1995-12-18 | 2011-02-08 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and methods of preparation of use |
| US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| DK2111876T3 (da) * | 1995-12-18 | 2011-12-12 | Angiodevice Internat Gmbh | Tværbundne polymerpræparater og fremgangsmåder til anvendelse deraf |
| US6833408B2 (en) * | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
| WO1998003670A1 (en) * | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
| US7118743B2 (en) | 1998-11-17 | 2006-10-10 | Tanox, Inc. | Bispecific molecules cross-linking ITIM and ITAM for therapy |
| AU1727500A (en) * | 1998-11-17 | 2000-06-05 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy |
| EP2281840A3 (en) | 2000-10-10 | 2012-05-23 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| US20020182172A1 (en) * | 2000-11-30 | 2002-12-05 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP3372243A1 (en) | 2001-08-17 | 2018-09-12 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| CN1604787A (zh) * | 2001-10-15 | 2005-04-06 | 希龙公司 | 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病 |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| CA2511521C (en) | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| WO2004060405A2 (en) * | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Tissue reactive compounds and compositions and uses thereof |
| JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| US20070110754A1 (en) | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| EP1684869B1 (en) | 2003-11-04 | 2011-07-20 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for b cell-related cancers |
| CA2544951A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| DE602004028643D1 (de) | 2003-11-04 | 2010-09-23 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens |
| JP5019881B2 (ja) | 2003-11-04 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびそれらを使用するための方法 |
| EP3476861A1 (en) | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
| US20050169970A1 (en) * | 2004-02-02 | 2005-08-04 | Unilever Bestfoods, North America | Food composition with fibers |
| EP1729791A2 (en) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| WO2006083260A2 (en) | 2004-04-28 | 2006-08-10 | Angiotech Biomaterials Corporation | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| WO2006034128A2 (en) | 2004-09-17 | 2006-03-30 | Angiotech Biomaterials Corporation | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
| ATE476994T1 (de) | 2004-11-30 | 2010-08-15 | Curagen Corp | Antikörper gegen gpnmb und ihre verwendungen |
| CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| US20060269556A1 (en) * | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
| AU2006272204A1 (en) * | 2005-07-21 | 2007-01-25 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
| EP1913028B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | Use of antibody to m-csf |
| EP2311876A3 (en) * | 2005-07-28 | 2011-04-27 | Novartis AG | M-CSF-specific monoclonal antibody and uses thereof |
| WO2007068255A1 (en) | 2005-12-15 | 2007-06-21 | Genmab A/S | Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| JP2009529915A (ja) | 2006-03-20 | 2009-08-27 | ゾーマ テクノロジー リミテッド | ガストリン物質に対して特異的なヒト抗体および方法 |
| CA2650126A1 (en) | 2006-04-13 | 2007-10-25 | Novartis Vaccines & Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancer |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| DK2426150T3 (en) | 2006-06-30 | 2018-01-22 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| CA2659820A1 (en) * | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| WO2008022295A2 (en) | 2006-08-18 | 2008-02-21 | Novartis Ag | Prlr-specific antibody and uses thereof |
| CN101687032A (zh) | 2006-12-07 | 2010-03-31 | 诺瓦提斯公司 | 抗ephb3的拮抗剂抗体 |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| TW201206954A (en) * | 2007-02-02 | 2012-02-16 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use |
| EP2125898B1 (en) | 2007-03-14 | 2013-05-15 | Novartis AG | Apcdd1 inhibitors for treating, diagnosing or detecting cancer |
| PT2222706E (pt) | 2007-12-14 | 2014-07-28 | Novo Nordisk As | Anticorpos contra nkg2d humano e utilizações dos mesmos |
| EP2261254A3 (en) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| AU2009207644A1 (en) | 2008-01-24 | 2009-07-30 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| CA2711826C (en) | 2008-01-25 | 2018-02-27 | Amgen Inc. | Ferroportin antibodies and methods of use |
| EP2294087B1 (en) | 2008-05-01 | 2014-05-14 | Amgen, Inc. | Anti-hepcidin antibodies and methods of use |
| EP3388527A1 (en) | 2008-05-15 | 2018-10-17 | Tetherex Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
| PE20141434A1 (es) | 2008-07-16 | 2014-10-22 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| WO2010007463A1 (en) | 2008-07-16 | 2010-01-21 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| JP5607620B2 (ja) * | 2008-07-25 | 2014-10-15 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗ａ型インフルエンザウイルス中和抗体およびその使用 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| MX2011002422A (es) * | 2008-09-08 | 2011-06-21 | Ottawa Hospital Res Inst | Regeneracion pancreatica inducida por periostina. |
| CN108610416B (zh) | 2008-10-13 | 2022-01-14 | 生物医学研究所 | 登革热病毒中和抗体及其用途 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| EP2408814B1 (en) | 2009-03-20 | 2018-11-21 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| JP2013511279A (ja) | 2009-11-20 | 2013-04-04 | アムジエン・インコーポレーテツド | 抗Ｏｒａｉ１抗原結合蛋白及びその使用 |
| WO2011092593A2 (en) | 2010-01-20 | 2011-08-04 | Institute For Research In Biomedicine | Hiv-1 neutralizing antibodies and uses thereof |
| CN103003307B (zh) | 2010-03-10 | 2017-08-11 | 根马布股份公司 | 抗c‑MEt的单克隆抗体 |
| NZ604003A (en) | 2010-05-27 | 2015-04-24 | Genmab As | Monoclonal antibodies against her2 |
| US9714294B2 (en) | 2010-05-27 | 2017-07-25 | Genmab A/S | Monoclonal antibodies against HER2 epitope |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| EP2619226B1 (en) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| AU2011335551B2 (en) | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
| HUE037992T2 (hu) | 2010-12-21 | 2018-09-28 | Selexys Pharmaceuticals Corp | Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására |
| US9493514B2 (en) | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| EP4520771A3 (en) | 2011-04-20 | 2025-07-16 | Genmab A/S | Bispecifc antibodies against her2 |
| WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
| CN116333113A (zh) | 2011-06-03 | 2023-06-27 | 佐马技术有限公司 | 对TGF-β具有特异性的抗体 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| US9587010B2 (en) | 2011-07-18 | 2017-03-07 | The Institute For Research In Biomedicine | Neutralizing anti-influenza A virus antibodies and uses thereof |
| NZ630920A (en) | 2012-03-20 | 2017-01-27 | Humabs Biomed Sa | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
| EP2859011B1 (en) | 2012-06-06 | 2019-12-11 | Bionor Immuno AS | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| EP2943506B1 (en) | 2013-01-10 | 2024-03-13 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| BR112015020587A2 (pt) | 2013-03-14 | 2017-10-10 | Regeneron Pharma | proteínas de fusão de apelina e suas utilizações |
| BR112015022123B1 (pt) | 2013-03-15 | 2022-08-09 | Intrinsic Lifesciences, Llc | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit |
| CN113667012B (zh) | 2013-10-02 | 2024-07-12 | 免疫医疗有限责任公司 | 中和抗甲型流感抗体及其用途 |
| CN106413738B (zh) | 2014-01-17 | 2020-12-29 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| WO2016007414A1 (en) | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| ME03665B (me) | 2014-07-11 | 2020-10-20 | Genmab As | Antitela koja vezuju axl |
| WO2016011035A2 (en) | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| EP3173074A4 (en) | 2014-07-22 | 2018-03-07 | Lemonex Inc. | Composition for delivering bioactive material or protein, and use thereof |
| AU2015294389B2 (en) | 2014-07-24 | 2021-04-29 | Genentech, Inc. | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
| EP3197915A4 (en) | 2014-09-22 | 2018-12-19 | Intrinsic Lifesciences LLC | Humanized anti-hepcidin antibodies and uses thereof |
| US20170296650A1 (en) | 2014-10-08 | 2017-10-19 | Novartis Ag | Combination of human cytomegalovirus neutralizing antibodies |
| ES2727154T3 (es) | 2014-10-24 | 2019-10-14 | Astrazeneca Ab | Combinación |
| CN107106669A (zh) | 2014-11-04 | 2017-08-29 | 南加利福尼亚大学 | 用于治疗过度表达HIF‑1α的癌症的组合物和方法 |
| WO2016075546A2 (en) | 2014-11-14 | 2016-05-19 | Antonio Lanzavecchia | Antibodies that neutralize ebola virus and uses thereof |
| HUE052595T2 (hu) | 2014-11-18 | 2021-05-28 | Humabs Biomed S A | Veszettség vírust és más lyssavirusokat hatékonyan semlegesítõ antitestek és alkalmazásaik |
| US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| EP3292139B1 (en) | 2015-05-05 | 2020-10-28 | The Regents of The University of California | H3.3 ctl peptides and uses thereof |
| US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| HRP20211510T1 (hr) | 2015-06-01 | 2021-12-24 | Medimmune, Llc | Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba |
| US20180179274A1 (en) | 2015-06-26 | 2018-06-28 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| ME03772B (me) | 2015-07-10 | 2021-04-20 | Genmab As | Konjugati antitijela specifičnog za axl i lijeka za liječenje kancera |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| EP3334453A4 (en) | 2015-08-13 | 2019-02-06 | New York University | ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP |
| EP3334761B1 (en) | 2015-08-13 | 2023-07-19 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| US9884920B2 (en) | 2015-10-09 | 2018-02-06 | Florida State University Research Foundation, Inc. | Antibodies specific for 4,6-diamino-5-(formamido)pyrimidine and uses thereof |
| AR108824A1 (es) | 2015-11-21 | 2018-10-03 | Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa | Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria |
| EP3402513A4 (en) | 2016-01-13 | 2019-10-23 | Medlmmune, LLC | METHOD FOR THE TREATMENT OF INFLUENZA A |
| GEP20217222B (en) | 2016-07-12 | 2021-02-10 | Lundbeck A/S H | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| WO2018067754A1 (en) | 2016-10-04 | 2018-04-12 | Fairbanks Pharmaceuticals, Inc. | Anti-fstl3 antibodies and uses thereof |
| BR112019008702A2 (pt) | 2016-11-01 | 2019-07-16 | Genmab B.V. | polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição. |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| EP3329905A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin |
| EP3329930A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
| ES2932498T3 (es) | 2016-12-05 | 2023-01-20 | Nuritas Ltd | Composiciones que comprenden el péptido WKDEAGKPLVK |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| JP7217710B2 (ja) | 2017-01-04 | 2023-02-03 | ハー・ルンドベック・アクチエゼルスカベット | 眼疾患の治療のための過リン酸化タウに特異的な抗体 |
| MX388358B (es) | 2017-02-06 | 2025-03-19 | Lemonex Inc | Portador de sustancia fisiologicamente activa. |
| WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| JP7278259B2 (ja) | 2017-04-19 | 2023-05-19 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | ワクチン及び標的としてのプラスモジウムスポロゾイトｎｐｄｐペプチド、新規マラリアワクチン、及びそれに結合する抗体 |
| CN111405910A (zh) | 2017-05-10 | 2020-07-10 | 阿尔巴朱纳治疗有限公司 | 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物 |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| US11530132B2 (en) | 2017-09-05 | 2022-12-20 | Lemonex Inc. | Composition comprising porous silica particles carrying a cell fate modulating factor |
| EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
| AU2019222705B2 (en) | 2018-02-14 | 2025-10-09 | Horizon Therapeutics Ireland Dac | Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases |
| EA202092593A1 (ru) | 2018-04-30 | 2021-02-12 | Такеда Фармасьютикал Компани Лимитед | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение |
| WO2019238962A1 (en) | 2018-06-14 | 2019-12-19 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
| WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
| WO2020132091A2 (en) | 2018-12-19 | 2020-06-25 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| TWI877141B (zh) | 2019-02-27 | 2025-03-21 | 美商Ionis製藥公司 | Malat1表現之調節劑 |
| EP3947441A1 (en) | 2019-03-27 | 2022-02-09 | UMC Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
| CN114040800B (zh) | 2019-04-09 | 2024-09-20 | 阿波科有限责任公司 | 杀伤细胞凝集素样受体亚家族g成员1(klrg1)耗竭抗体 |
| EP3783012A1 (en) | 2019-08-20 | 2021-02-24 | Nuritas Limited | An antimicrobial peptide |
| CN114650834A (zh) | 2019-08-20 | 2022-06-21 | 努里塔斯有限公司 | 用于治疗肌肉萎缩的肽 |
| KR20220063188A (ko) | 2019-08-29 | 2022-05-17 | 비르 바이오테크놀로지, 인코포레이티드 | B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법 |
| KR20220109391A (ko) | 2019-10-22 | 2022-08-04 | 뉴리타스 리미티드 | 비-알콜성 지방간 질환의 치료 |
| EP3862014A1 (en) | 2020-02-07 | 2021-08-11 | Nuritas Limited | Treatment of panx1 associated diseases |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP4171747A1 (en) | 2020-06-24 | 2023-05-03 | VIR Biotechnology, Inc. | Engineered hepatitis b virus neutralizing antibodies and uses thereof |
| US20250277044A1 (en) | 2021-01-08 | 2025-09-04 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody |
| KR20230129483A (ko) | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Pd-l1과 특이적으로 결합하는 항체 및 그 항원 결합단편 |
| JP7699210B2 (ja) | 2021-01-08 | 2025-06-26 | 北京韓美薬品有限公司 | Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント |
| JP2024504167A (ja) | 2021-01-26 | 2024-01-30 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| KR20230162798A (ko) | 2021-03-26 | 2023-11-28 | 압큐로, 인크. | 항-klrg1 항체 |
| WO2022212836A1 (en) | 2021-04-01 | 2022-10-06 | Pyxis Oncology, Inc. | Gpnmb antibodies and methods of use |
| WO2022219008A1 (en) | 2021-04-14 | 2022-10-20 | University College Cork - National University Of Ireland, Cork | Treatment of cerebrovascular events and neurological disorders |
| WO2022219168A1 (en) | 2021-04-14 | 2022-10-20 | University College Cork - National University Of Ireland, Cork | Psg1 for use in the treatment of osteoarthritis |
| CA3227742A1 (en) | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| WO2023105281A1 (en) | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
| CN117586388A (zh) | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 改进的β淀粉样蛋白寡聚体特异性结合抗体 |
| CN117589996A (zh) | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 强毒性淀粉样蛋白寡聚体的诊断用途 |
| JP2025534040A (ja) | 2022-10-14 | 2025-10-09 | ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク | 腱傷害の治療における使用のための胎盤発現タンパク質 |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2222080A1 (en) * | 1973-03-22 | 1974-10-18 | Viejo Jacques | Stabilisation of pepsin - by salt formation with a carboxy polymethylene |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5623587A (en) * | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| SU1022988A1 (ru) * | 1979-09-28 | 1983-06-15 | Всесоюзный кардиологический научный центр АМН СССР | Стабилизированна урокиназа,обладающа тромболитической активностью,и способ ее получени |
-
1981
- 1981-10-30 JP JP56172908A patent/JPS5896026A/ja active Granted
-
1982
- 1982-10-27 BR BR8206347A patent/BR8206347A/pt unknown
- 1982-10-27 US US06/437,009 patent/US4495285A/en not_active Expired - Fee Related
- 1982-10-28 CH CH6304/82A patent/CH658669A5/fr not_active IP Right Cessation
- 1982-10-29 CA CA000414556A patent/CA1203764A/en not_active Expired
- 1982-10-29 FR FR8218223A patent/FR2515684B1/fr not_active Expired
- 1982-10-29 SE SE8206173A patent/SE457800B/sv not_active IP Right Cessation
- 1982-10-29 GB GB08230987A patent/GB2110219B/en not_active Expired
- 1982-10-29 DE DE19823240174 patent/DE3240174A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2110219A (en) | 1983-06-15 |
| GB2110219B (en) | 1985-01-09 |
| SE8206173L (sv) | 1983-05-01 |
| BR8206347A (pt) | 1983-09-27 |
| SE8206173D0 (sv) | 1982-10-29 |
| US4495285A (en) | 1985-01-22 |
| DE3240174A1 (de) | 1983-05-19 |
| US4495285B1 (enExample) | 1986-09-23 |
| JPH0525470B2 (enExample) | 1993-04-13 |
| CA1203764A (en) | 1986-04-29 |
| JPS5896026A (ja) | 1983-06-07 |
| FR2515684A1 (fr) | 1983-05-06 |
| CH658669A5 (fr) | 1986-11-28 |
| FR2515684B1 (fr) | 1986-04-04 |
| SE457800B (sv) | 1989-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3240174C2 (enExample) | ||
| DE3400413C2 (enExample) | ||
| DE69433133T2 (de) | Lösliches thrombomodulin enthaltende zubereitung | |
| CH645537A5 (en) | Antithrombin product and process for its production | |
| DE2459291C3 (de) | Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen | |
| DE3150318C2 (de) | "Verfahren zur Herstellung eines Polysaccharidderivats des Fibrinolysins" | |
| DE69020276T2 (de) | Amylose-Lysozym-Hybrid, ein Aktivzucker und Verfahren zur Herstellung. | |
| EP0181465A1 (de) | Blutgerinnungshemmende Proteine, Verfahren zur Herstellung sowie deren Verwendung | |
| DE2943512A1 (de) | Antihaemophiliefaktorpraeparat und verfahren zu seiner herstellung | |
| EP2293776A2 (de) | Lagerstabiles, funktionell intaktes fibrinogen | |
| CH637992A5 (de) | Verfahren zur herstellung eines komplexes aus streptokinase und einer leichten (b) plasmin-kettenfraktion mit einem aktiven serinprotease-zentrum. | |
| EP0625908B1 (de) | Antidot für hirudin und synthetische thrombininhibitoren | |
| DE3872534T2 (enExample) | ||
| DE2459915C3 (de) | Aktive Verbindung des Plasminogen- Typs, Verfahren zu ihrer Reinigung und ihre Verwendung | |
| DE69425581T2 (de) | Methode zur stabilisierung von protein c oder aktiviertem protein c und stabilisierte verbindungen | |
| DE69727736T2 (de) | Verfahren zur Aktivierung von Prothrombin zu Thrombin | |
| DE1442134C3 (de) | In vivo antikoagulierend wirkendes und defibrinierendes Enzym | |
| DE69023470T2 (de) | Pasteurisierensverfahren und pasteurisierter kleber zum binden von menschlichen oder tierischen geweben. | |
| DE3586952T2 (de) | Fibrinophiler urokinase-komplex und dessen herstellung. | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| DE68907718T2 (de) | Verfahren zur pasteurisierung von wässrigen lösungen von faktor viii. | |
| DE19726626C1 (de) | Verfahren zur Herstellung eines eine Hyaluronidase enthaltenden Präparats | |
| DE1617279C3 (de) | Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel | |
| AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
| DE2855698C2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |